Hemophagocytic lymphohistiocytosis secondary to epstein-barr virus reactivation in a patient with COVID-19
Published: 16 February 2022
Archives of Hematology Case Reports and Reviews , Volume 7, pp 006-008; https://doi.org/10.17352/ahcrr.000036
Abstract: Hemophagocytic Lymphohistiocytosis (HLH) in coronavirus disease 2019 (COVID-19) is a recognized complication of severe illness. However, this phenomenon has been reported most often in the setting of acute infection. Here we present a case of a patient with a history of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection that subsequently developed HLH weeks after treatment of COVID-19 and discharges from the hospital. Upon re-admission, work-up demonstrated the patient was experiencing Epstein-Barr virus (EBV) reactivation. As EBV infection is a known etiological trigger of HLH, this case provides an alternative mechanism for HLH seen in patients with a history of COVID-19 infection who present after the resolution of acute symptomatology.
Keywords: HLH / COVID / Hemophagocytic lymphohistiocytosis / epstein barr virus
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Click here to see the statistics on "Archives of Hematology Case Reports and Reviews" .